• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

过氧化物酶 1 表达对实体瘤患者预后的预测价值：队列研究的荟萃分析。

Prognostic Value of Peroxiredoxin-1 Expression in Patients with Solid Tumors: a Meta-Analysis of Cohort Study.

机构信息

Department of Thyroid and Breast Surgery, Taizhou People's Hospital, Taizhou, 225300 Jiangsu Province, China.

Department of Obstetrics and Gynecology, Taizhou People's Hospital, Taizhou, 225300 Jiangsu Province, China.

出版信息

Dis Markers. 2021 Mar 3;2021:9508702. doi: 10.1155/2021/9508702. eCollection 2021.

DOI:10.1155/2021/9508702
PMID:33747258
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7952178/
Abstract

METHODS

We comprehensively searched electronic databases, namely, PubMed, Web of Science, EMBASE, Chinese National Knowledge Infrastructure (CNKI), and WanFang databases up to December 2019. Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated to evaluate the association between PRDX1 protein expression and the survival of patients with solid tumors. Odds ratios (ORs) with 95% CIs were pooled to estimate the correlation between PRDX1 protein expression and clinicopathologic characteristics in the patients.

RESULTS

Seventeen cohort studies that involved 2,858 patients were included in this meta-analysis. The pooled results indicated that positive PRDX1 expression was related to poor overall survival (HR = 1.68, 95% CI: 1.24-2.27, = 0.001) and disease-free survival (HR = 1.88, 95% CI: 1.31-2.70, = 0.001). In addition, high PRDX1 expression was associated with large tumor size (OR = 1.69, 95% CI: 1.07-2.68, = 0.025), advanced TNM stage (OR = 2.26, 95% CI: 1.24-4.13, = 0.008), and poor tumor differentiation (OR = 0.59, 95% CI: 0.44-0.81, = 0.001).

CONCLUSIONS

PRDX1 overexpression is associated with poor outcomes of cancers and may serve as a prognostic biomarker for malignant patients. Hence, PRDX1 could be a new target for antitumor therapy.

摘要

方法

我们全面检索了电子数据库，包括 PubMed、Web of Science、EMBASE、中国知网（CNKI）和万方数据库，检索时间截至 2019 年 12 月。使用风险比（HR）及其 95%置信区间（CI）评估 PRDX1 蛋白表达与实体瘤患者生存之间的关系。使用优势比（OR）及其 95%CI 评估 PRDX1 蛋白表达与患者临床病理特征之间的相关性。

结果

本荟萃分析共纳入了 17 项队列研究，涉及 2858 例患者。汇总结果表明，PRDX1 阳性表达与总生存不良（HR=1.68，95%CI：1.24-2.27， =0.001）和无病生存不良（HR=1.88，95%CI：1.31-2.70， =0.001）相关。此外，PRDX1 高表达与肿瘤较大（OR=1.69，95%CI：1.07-2.68， =0.025）、TNM 分期较晚（OR=2.26，95%CI：1.24-4.13， =0.008）和肿瘤分化不良（OR=0.59，95%CI：0.44-0.81， =0.001）相关。

结论

PRDX1 过表达与癌症不良预后相关，可能成为恶性肿瘤患者的预后生物标志物。因此，PRDX1 可能成为抗肿瘤治疗的新靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9601/7952178/da0484c79e19/DM2021-9508702.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9601/7952178/9263f49e45a8/DM2021-9508702.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9601/7952178/c9898c7cf4d9/DM2021-9508702.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9601/7952178/5f4deb37941f/DM2021-9508702.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9601/7952178/a7febdc6a69a/DM2021-9508702.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9601/7952178/da0484c79e19/DM2021-9508702.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9601/7952178/9263f49e45a8/DM2021-9508702.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9601/7952178/c9898c7cf4d9/DM2021-9508702.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9601/7952178/5f4deb37941f/DM2021-9508702.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9601/7952178/a7febdc6a69a/DM2021-9508702.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9601/7952178/da0484c79e19/DM2021-9508702.005.jpg

相似文献

1
Prognostic Value of Peroxiredoxin-1 Expression in Patients with Solid Tumors: a Meta-Analysis of Cohort Study.过氧化物酶 1 表达对实体瘤患者预后的预测价值：队列研究的荟萃分析。
Dis Markers. 2021 Mar 3;2021:9508702. doi: 10.1155/2021/9508702. eCollection 2021.
2
The clinicopathologic impacts and prognostic significance of GLUT1 expression in patients with lung cancer: A meta-analysis.GLUT1 表达在肺癌患者中的临床病理影响及预后意义：一项荟萃分析。
Gene. 2019 Mar 20;689:76-83. doi: 10.1016/j.gene.2018.12.006. Epub 2018 Dec 12.
3
Association between Alpha B-crystallin expression and prognosis in patients with solid tumors: A protocol for systematic review and meta-analysis.αB-晶状体蛋白表达与实体瘤患者预后的相关性：系统评价和荟萃分析方案。
Medicine (Baltimore). 2021 Feb 19;100(7):e24831. doi: 10.1097/MD.0000000000024831.
4
Clinicopathological and prognostic value of SNHG6 in cancers: a systematic review and a meta-analysis.SNHG6 在癌症中的临床病理和预后价值：系统评价和荟萃分析。
BMC Cancer. 2020 Apr 22;20(1):343. doi: 10.1186/s12885-020-06850-0.
5
Prognostic value of long non-coding RNA FOXD2-AS1 expression in patients with solid tumors.长链非编码 RNA FOXD2-AS1 表达对实体瘤患者的预后价值。
Pathol Res Pract. 2019 Sep;215(9):152449. doi: 10.1016/j.prp.2019.152449. Epub 2019 Jun 8.
6
Prognostic value of lncRNA FEZF1 antisense RNA 1 over-expression in oncologic outcomes of patients with solid tumors.长链非编码RNA FEZF1反义RNA 1过表达在实体瘤患者肿瘤学预后中的预测价值
Medicine (Baltimore). 2019 Jun;98(24):e15982. doi: 10.1097/MD.0000000000015982.
7
ILK and PRDX1 are prognostic markers in squamous cell/adenosquamous carcinomas and adenocarcinoma of gallbladder.整合素连接激酶（ILK）和过氧化物还原酶1（PRDX1）是胆囊鳞状细胞癌/腺鳞癌及腺癌的预后标志物。
Tumour Biol. 2013 Feb;34(1):359-68. doi: 10.1007/s13277-012-0557-2. Epub 2012 Oct 13.
8
Low NDRG2 expression predicts poor prognosis in solid tumors: A meta-analysis of cohort study.低NDRG2表达预示实体瘤预后不良：一项队列研究的荟萃分析
Medicine (Baltimore). 2020 Oct 9;99(41):e22678. doi: 10.1097/MD.0000000000022678.
9
Prognostic significance of LINC00460 overexpression in solid tumours: a meta-analysis.LINC00460 过表达在实体瘤中的预后意义：一项荟萃分析。
Postgrad Med J. 2020 May;96(1135):286-295. doi: 10.1136/postgradmedj-2019-137172. Epub 2020 Feb 13.
10
LncRNA LINC00460 promotes EMT in head and neck squamous cell carcinoma by facilitating peroxiredoxin-1 into the nucleus.长链非编码 RNA LINC00460 通过促进过氧化物酶 1 进入细胞核促进头颈部鳞状细胞癌中的 EMT。
J Exp Clin Cancer Res. 2019 Aug 20;38(1):365. doi: 10.1186/s13046-019-1364-z.

引用本文的文献

1
Recent Insights into the Biomarkers, Molecular Targets and Mechanisms of Non-Alcoholic Steatohepatitis-Driven Hepatocarcinogenesis.非酒精性脂肪性肝炎驱动的肝癌发生的生物标志物、分子靶点和机制的最新见解
Cancers (Basel). 2023 Sep 14;15(18):4566. doi: 10.3390/cancers15184566.
2
Increased Sphingosine Kinase 1 Expression Is Associated with Poor Prognosis in Human Solid Tumors: A Meta-Analysis.丝氨酸棕榈酰转移酶 1 表达增加与人类实体瘤预后不良相关：一项荟萃分析。
Dis Markers. 2022 Jan 28;2022:8443932. doi: 10.1155/2022/8443932. eCollection 2022.

本文引用的文献

1
The Value of lncRNA GHET1 as a Prognostic Factor for Survival of Chinese Cancer Outcome: A Meta-Analysis.lncRNA GHET1 作为中国癌症患者生存预后的预测因子的价值：一项荟萃分析。
Dis Markers. 2019 Dec 1;2019:5824190. doi: 10.1155/2019/5824190. eCollection 2019.
2
Geriatric Nutritional Risk Index Predicts Adverse Outcomes in Human Malignancy: A Meta-Analysis.老年营养风险指数预测人类恶性肿瘤不良结局：一项荟萃分析。
Dis Markers. 2019 Nov 19;2019:4796598. doi: 10.1155/2019/4796598. eCollection 2019.
3
Prognostic value of high stanniocalcin 2 expression in solid cancers: A meta-analysis.
高骨钙素2在实体癌中的预后价值：一项荟萃分析。
Medicine (Baltimore). 2019 Oct;98(43):e17432. doi: 10.1097/MD.0000000000017432.
4
Peroxiredoxin-1 as a prognostic factor in patients with ovarian cancer.过氧化物酶体增殖物激活受体-1作为卵巢癌患者的预后因素。
Ann Agric Environ Med. 2019 Sep 19;26(3):415-419. doi: 10.26444/aaem/105899. Epub 2019 Apr 1.
5
The Role of Peroxiredoxin Family in Cancer Signaling.过氧化物还原酶家族在癌症信号传导中的作用。
J Cancer Prev. 2019 Jun;24(2):65-71. doi: 10.15430/JCP.2019.24.2.65. Epub 2019 Jun 30.
6
Peroxiredoxin-5 is a negative survival predictor in ovarian cancer.过氧化物酶体增殖物激活受体5是卵巢癌的负性生存预测指标。
Ginekol Pol. 2019;90(1):1-6. doi: 10.5603/GP.2019.0001.
7
Prognostic roles of mRNA expression of peroxiredoxins in lung cancer.过氧化物还原酶的mRNA表达在肺癌中的预后作用。
Onco Targets Ther. 2018 Nov 27;11:8381-8388. doi: 10.2147/OTT.S181314. eCollection 2018.
8
Decreased expression of peroxiredoxin1 inhibits proliferation, invasion, and metastasis of ovarian cancer cell.过氧化物还原酶1表达降低抑制卵巢癌细胞的增殖、侵袭和转移。
Onco Targets Ther. 2018 Nov 2;11:7745-7761. doi: 10.2147/OTT.S175009. eCollection 2018.
9
Prognostic significance of CXCL5 expression in cancer patients: a meta-analysis.CXCL5表达在癌症患者中的预后意义：一项荟萃分析。
Cancer Cell Int. 2018 May 2;18:68. doi: 10.1186/s12935-018-0562-7. eCollection 2018.
10
Peroxiredoxin 1 promoted tumor metastasis and angiogenesis in colorectal cancer.过氧化物酶体增殖物激活受体1促进结直肠癌的肿瘤转移和血管生成。
Pathol Res Pract. 2018 May;214(5):655-660. doi: 10.1016/j.prp.2018.03.026. Epub 2018 Apr 3.